In early 2017, we initiated the first cases of AROmotion, a pioneering nonsurgical alternative to total joint replacement, combining radiofrequency ablation, orthobiologic therapies, and total joint reconditioning. From those first cases in 2017 through the end of Q3 2022, we have surpassed 3,000 procedures. AROmotion is the largest and only provider of nonsurgical RFA with orthobiologic procedures and patient-centric reconditioning protocols.
Our physicians are trained observers conducting a multi-year, structured research protocol measuring both pre- and post-procedural outcomes in our over 3,000 cases. The results since launching our clinical case series show that AROmotion has consistently outperformed total joint replacement surgery.
We follow each patient’s pre- and post-procedure data using the WOMAC Data Model, collected for 5 years. Our improvement in scores unequivocally shows lasting improvement that exceeds patients who have undergone total joint replacement surgery.